Regenerative medicine crossing borders

 

 

RegMed XB

Dutch and Flemish Prime Ministers sign a strategic research agreement

On November 7th, Prime Ministers Mark Rutte and Geert Bourgeois signed a strategic agreement in Gent, describing a close collaboration in regenerative medicine research. The signing of this agreement means the Flanders Institute for Biotechnology (VIB) and the Dutch RegMed XB Institute, including the universities of Leiden, Utrecht, Eindhoven and Maastricht, will partner for high quality state of the art research. Photo © Stad Gent.

Phase 1 of RegMed XB begins

Scientists and physicians from the universities and involved institutes of Utrecht, Maastricht, Leiden and Eindhoven will be working together. A partnership with the business community provides the basis for a new, high-quality industry within our national borders. This is why the Province of Utrecht, the Province of Noord-Brabant, the Province of Limburg and the municipality of Leiden are now expressing their intention to support the partnership. 

Phase 1 of RegMed XB begins

On 05 July 2016, many of the partners met to initiate Phase 1. RegMed XB brings together scientists and physicians from universities, regional governments, and businesses for common goals in regenerative medicine.

Health foundations collaborate in Phase 1

Mark Seubert (Scientific Council Member, DON Foundation) and Hanneke Dessing (Director, Diabetes Fonds) discuss the cooperation of their respective foundations in RegMed XB. Thanks to their support, one of the Phase 1 projects is to develop a new therapy against type 1 diabetes.

1
2
3
4

A robust new institute for regenerative medicine

Regenerative medicine aims to restore degenerated, diseased or damaged tissues and organs, thereby increasing vital functioning and reducing the cost of healthcare. RegMed XB brings together multiple health foundations, top scientists, entrepreneurs and governments to cooperatively tackle ambitious challenges in regenerative medicine. In RegMed XB, research and clinical translation are integrated to quickly and optimally bring research results into patient solutions and new businesses.